Status:
NOT_YET_RECRUITING
A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
Lead Sponsor:
Xuhua Duan
Conditions:
Hepatocellular Carcinoma (HCC)
Eligibility:
All Genders
18+ years
Brief Summary
The system assesses the heterogeneity of HCC patients in terms of therapeutic outcomes (such as rwPFS, ORR, PRO) and adverse reactions during the process of interventional therapy combined with system...
Eligibility Criteria
Inclusion
- 1\. Age ≥ 18 years old, gender not restricted; 2. Diagnosed with HCC through pathological or imaging examination, and meeting the diagnostic criteria of the "Primary Liver Cancer Diagnosis and Treatment Guidelines (2024 Edition)"; 3. Has received or plans to receive interventional therapy combined with systemic treatment (including but not limited to DEB-TACE combined with targeted therapy, DEB-TACE combined with targeted therapy and immunotherapy, DEB-TACE combined with targeted therapy and immunotherapy other local interventional treatments (such as HAIC, ablation, particle implantation, etc.)); 4. Has completed baseline clinical information and treatment records, can cooperate with the follow-up arrangement, and has the willingness and ability to complete the entire research process; 5. Signed the informed consent form.
Exclusion
- 1\. Diagnosed with liver metastatic cancer or other primary malignant tumors that are not HCC, or with concurrent other active primary malignant tumors; 2. Clearly have severe cognitive impairment, mental illness or confusion, and are unable to cooperate with the visit or fill out the scale; 3. Expected survival period is less than 3 months or clinical judgment indicates that follow-up cannot be completed; 4. Liver function is in decompensation, with Child-Pugh classification as C; 5. The investigator considers any other situation that is not suitable for participating in this study.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2028
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT07156617
Start Date
October 1 2025
End Date
October 1 2028
Last Update
September 5 2025
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Hainan Medical Universsity
Haikou, Hainan, China
2
Xingtai No.5 Hospital
Xingtai, Hebei, China
3
Deng zhou People's Hospital
Dengzhou, Henan, China
4
The Second People's Hospital of Jiaozuo
Jiaozuo, Henan, China